Oral Psoriasis Drug with $200 Million Option Revenue: A Bio Company Filling Its Cash Reserves

On the 5th, Protagonist Therapeutics, Inc. (PTGX) released its first-quarter 2026 financial results and corporate update. The company reported that it received a $50 million milestone payment following FDA approval of ICOTYDE, its oral therapy for moderate-to-severe plaque psoriasis, and has secured tiered royalties of 6–10% of net sales plus up to $580 million in additional milestone rights. Protagonist also disclosed that the U.S. New Drug Application for rusfertide, its candidate for polycythemia vera, has been granted FDA Priority Review with a target action date in August 2026. Furthermore, on April 28 the company exercised its option to exit the U.S. profit-and-loss sharing arrangement with Takeda for rusfertide, triggering an immediate $200 million opt-out payment. At the end of the quarter, Protagonist held $620.3 million in cash, cash equivalents and marketable securities—resources management says will fund operations through at least 2028. Thanks to the ICOTYDE milestone and cost reimbursements from Takeda, the company swung from a net loss in the year-ago period to a net profit of $3.8 million.

In March, the FDA approved ICOTYDE—developed jointly by Johnson & Johnson and Protagonist—as the first targeted, oral interleukin-23 receptor antagonist for adult and adolescent patients with moderate-to-severe plaque psoriasis. Analysts expect its oral formulation to reshape competitive dynamics across the psoriasis market. In late April, Takeda announced that, following Protagonist’s opt-out, it now holds exclusive U.S. development and commercialization rights to rusfertide. Under the revised deal, Protagonist can earn up to $975 million in regulatory and sales milestones and tiered royalties ranging from 14% to 29%.

Protagonist Therapeutics is a U.S. biotech company developing orally administered, peptide-based therapies for immune, inflammatory and hematologic disorders. Its core pipeline—ICOTYDE for psoriasis and rusfertide for polycythemia vera—targets large patient populations in need of long-term treatment, areas that global pharmaceutical leaders such as Johnson & Johnson and Takeda are aggressively pursuing.